A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN 115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Trial Profile

A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN 115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Tozadenant (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 08 Jun 2017 Results of a post-hoc analysis from this trial presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 19 Jan 2016 Results published in an Acorda Therapeutics media release.
    • 20 Feb 2015 According to Biotie Therapies media release, it expects that the Phase 2b study will be considered the first of two pivotal studies required for registration for tozadenant in PD patients with end-of-dose 'wearing-off'.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top